- CEO
- Zhao Wu Leng
- Full Time Employees
- 810
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Shanghai China
- IPO Date
- Dec 28, 2021
- Business
- Shanghai Universal Biotech Co., Ltd. is a China-based life science platform enterprise engaged in the research, development, supply, and provision of comprehensive biotechnology research reagents, laboratory consumables, analytical instruments, and contract experimental services. Founded in 2004 and headquartered in Shanghai, China, the company operates as a one-stop procurement and solutions provider serving academic universities, scientific research institutes, medical centers, hospitals, contract research organizations, biopharmaceutical enterprises, and in vitro diagnostic manufacturers across domestic and international markets.
The company delivers an integrated product and service portfolio organized across core life science research categories, including: life science research reagents, comprising primary and secondary antibodies, recombinant proteins, biochemical reagents, molecular biology kits, cell culture media, and enzyme-linked immunosorbent assay (ELISA) kits; laboratory consumables, such as cell culture plates, dishes, flasks, pipette tips, filtration units, PCR plasticware, and cryopreservation containers; laboratory instruments and equipment, featuring flow cytometers, microplate readers, Western blot imaging systems, automated liquid handlers, centrifuges, and benchtop analytical devices; and technical and experimental research services, including custom antibody preparation, flow cytometry testing, proteomics analysis, immunohistochemistry (IHC) services, multi-omics assay support, and single-cell sequencing services. The company supplies its catalog through an extensive network of international brand distributions alongside proprietary brand labels, including Univ and Absin.
In recent developments, Shanghai Universal Biotech Co., Ltd. has accelerated the strategic expansion of its proprietary research and development capabilities, substantially increasing the scale and variety of its self-developed antibody products, molecular diagnostic reagents, and specialty biochemicals to enhance supply independence. The company has expanded its technical service segment by launching advanced service platforms dedicated to spatial multi-omics, high-throughput flow cytometry screening, and recombinant antibody engineering. Furthermore, the company has strengthened its nationwide supply chain infrastructure through the continuous optimization of regional temperature-controlled cold-chain logistics centers across major Chinese biomedical clusters, upgraded its proprietary e-commerce and digital procurement platform (Univ-Mall), and established collaborative strategic supply agreements with life science component manufacturers to extend product availability and broaden market coverage.